EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Melatonin Overcomes Cancer Multidrug Resistance by Downregulating ABCB1 Expression and Modulating Mitochondrial Function

Alba López-Rodríguez, Laura Martinez-Ruiz, Raquel Morales-Gallel, Javier Florido, Fabiola Bermejo-Casares, José Manuel Garcia-Verdugo, María Martín Estebané, Víctor Carriel, Noelia Maldonado-Pérez, Pilar González-García, Seyedeh T Ahmadpour, Yolanda Ramírez-Casas und 6 weitere

Journal of Pineal Research · 2025-11 · 77 (6)

DOI: 10.1111/jpi.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pineal Research, online erschienen am 04.11.2025. Verfasst von Alba López-Rodríguez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain. Hauptthemen laut MEDLINE: Melatonin, Mitochondria, Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug resistance (MDR) is a major challenge in cancer chemotherapy. A critical factor contributing to MDR is overexpression of ATP‐binding cassette (ABC) transporters, such as ABCB1. Novel alternative therapeutic strategies are needed to overcome resistance associated with ABC transporters. In the present study, we aimed to elucidate the mechanisms by which melatonin overcomes ABCB1‐mediated MDR in cancer cells, with a focus on mitochondrial function. We analyzed the effects of melatonin (1 mM) on head and neck squamous cell carcinoma cell lines (CAL 27 and SCC‐9) overexpressing ABCB1 and exhibiting increased resistance to cisplatin (CDDP) compared to their parental cells. To further validate the role of melatonin in reversing ABCB1‐mediated MDR, we also evaluated its effects on doxorubicin‐resistant MCF‐7 breast cancer cells. We further examined the potential of melatonin to overcome MDR in CAL 27 xenografted mice. Here, we report that melatonin treatment specifically triggered reactive oxygen species (ROS) production in mitochondria and weakened chemoresistance. ROS oxidized NADH into NAD + , and limiting the availability of ATP for efflux pump activity. Additionally, melatonin decreased the number of mitochondria localized near the nucleus instead of the cytoplasm and downregulated ABCB1 expression. Intratumoral administration of melatonin effectively overcame CDDP resistance in CAL 27/ABCB1 xenografts, significantly reducing tumor volume and promoting apoptosis. These findings demonstrate that melatonin enhances chemosensitivity in ABCB1‐overexpressing cells by modulating mitochondrial metabolism, redox balance, and ABCB1 expression, highlighting its potential as an adjuvant therapy to overcome MDR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninMitochondriaDrug Resistance, NeoplasmDrug Resistance, MultipleGene Expression Regulation, NeoplasticHumansAnimalsATP Binding Cassette Transporter, Subfamily BMiceDown-RegulationCell Line, TumorReactive Oxygen SpeciesMCF-7 CellsXenograft Model Antitumor AssaysMice, NudeFemaleCisplatin

Stichwörter der Autor:innen

P‐glycoproteinapoptosishead and neck cancermelatoninmitochondriamultidrug resistancereactive oxygen species

Substanzen

MelatoninABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BReactive Oxygen SpeciesCisplatin

Autor:innen und Institutionen

  • Institute of Biotechnology, Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.
  • Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain.
  • Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Investigación Biosanitaria (Ibs), Granada, San Cecilio University Hospital, Granada, Spain.
  • Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain.
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Department of Histology, Tissue Engineering Group, Faculty of Medicine, University of Granada, Granada, Spain.

ORCID-Profile: Yang Yang, Germaine Escames

Zitieren

APA

López-Rodríguez, A., Martinez-Ruiz, L., Morales-Gallel, R., Florido, J., Bermejo-Casares, F., Garcia-Verdugo, J. M., Estebané, M. M., Carriel, V., Maldonado-Pérez, N., González-García, P., Ahmadpour, S. T., Ramírez-Casas, Y., Martín, F., Dumas, J. F., Vandier, C., Yang, Y., Acuña-Castroviejo, D., & Escames, G. (2025). Melatonin Overcomes Cancer Multidrug Resistance by Downregulating ABCB1 Expression and Modulating Mitochondrial Function. Journal of Pineal Research, 77(6). https://doi.org/10.1111/jpi.70096

Vancouver

López-Rodríguez A, Martinez-Ruiz L, Morales-Gallel R, Florido J, Bermejo-Casares F, Garcia-Verdugo JM, et al. Melatonin Overcomes Cancer Multidrug Resistance by Downregulating ABCB1 Expression and Modulating Mitochondrial Function. Journal of Pineal Research. 2025;77(6). doi:10.1111/jpi.70096

BibTeX
@article{LpezRodrguez2025,
  author = {López-Rodríguez, Alba and Martinez-Ruiz, Laura and Morales-Gallel, Raquel and Florido, Javier and Bermejo-Casares, Fabiola and Garcia-Verdugo, José Manuel and Estebané, María Martín and Carriel, Víctor and Maldonado-Pérez, Noelia and González-García, Pilar and Ahmadpour, Seyedeh T and Ramírez-Casas, Yolanda and Martín, Francisco and Dumas, Jean-Francois and Vandier, Christophe and Yang, Yang and Acuña-Castroviejo, Darío and Escames, Germaine},
  title = {Melatonin Overcomes Cancer Multidrug Resistance by Downregulating ABCB1 Expression and Modulating Mitochondrial Function},
  journal = {Journal of Pineal Research},
  year = {2025},
  volume = {77},
  number = {6},
  doi = {10.1111/jpi.70096}
}
Kostenlos starten →